SCHEMBL898414

SCHEMBL898414

CC1(C)OC(CO)C(CO[Si](C)(C)C(C)(C)C)O1

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 5/20 0.34
▸ MAPT P10636 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TOP2A P11388 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15659482 1.00 CYP3A4 (0.34) CYP3A4MAPTHPGDTOP2A
SCHEMBL897160 1.00 CYP3A4 (0.34) CYP3A4MAPTHPGDTOP2A
SCHEMBL17627244 1.00 CYP3A4 (0.34) CYP3A4MAPTHPGDTOP2A
SCHEMBL15659627 1.00 CYP3A4 (0.34) CYP3A4MAPTHPGDTOP2A
SCHEMBL6825515 1.00 CYP3A4 (0.34) CYP3A4MAPTHPGDTOP2A
SCHEMBL23489728 0.90 MAPT (0.33) MAPTHPGDTOP2A
SCHEMBL15661135 0.89 CYP3A4 (0.32) CYP3A4MAPTHPGD
SCHEMBL15657817 0.89 CYP3A4 (0.32) CYP3A4MAPTHPGD
SCHEMBL15660928 0.89 CYP3A4 (0.32) CYP3A4MAPTHPGD
SCHEMBL17913474 0.87 CYP3A4 (0.33) CYP3A4TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
EP-3613729-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-02-26 — — EP disclosed
EP-3345903-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2019-10-09 — — EP disclosed
EP-3345903-A1 TETRACYCLIC COMPOUNDS Chugai Seiyaku Kabushiki Kaisha (JP) 2018-07-11 — — EP disclosed
EP-2975024-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2018-03-28 — — EP disclosed
US-20160340308-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-24 — — US disclosed
US-9440922-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-09-13 — — US disclosed
EP-2441753-B1 TETRACYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2016-03-30 — — EP disclosed
EP-2975024-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-20 — — EP disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 — — US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
EP-2441753-A1 TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2012-04-18 — — EP disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CYP3A4 2585/4885MAPT 68/4885HPGD 4633/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CYP3A4 2585/4885MAPT 68/4885HPGD 4633/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CYP3A4 2585/4885MAPT 68/4885HPGD 4633/4885
US-20160340308-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CYP3A4 2585/4885MAPT 68/4885HPGD 4633/4885
US-20150150845-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CYP3A4 2585/4885MAPT 68/4885HPGD 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback